EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report
Abstract
BackgroundLeptomeningeal metastasis (LM) is a severe complication of advanced non-small cell lung cancer (NSCLC). Conventional cerebrospinal fluid (CSF) cytology has limited sensitivity and often delays diagnosis. We report a case of LM molecularly supported by CSF next-generation sequencing (NGS) after three negative cytological examinations. NGS also revealed a potential bypass resistance alteration that informed subsequent treatment considerations.CaseA 57-year-old female never-smoker had EGFR exon 21 p.L858R-mutant lung adenocarcinoma. After 18 months of first-line osimertinib (80 mg once daily), she developed progressive nausea, vomiting, and dizziness. Contrast-enhanced cranial magnetic resonance imaging (MRI) showed linear leptomeningeal enhancement. Lumbar puncture showed markedly elevated intracranial pressure (>300 mmH2O) and increased CSF protein. However, three CSF cytological examinations (including cell block sections) found no malignant cells. CSF NGS detected the EGFR p.L858R mutation identical to the primary tumor, together with CDK4 amplification. Integrated with the clinical and MRI presentation, these findings supported a diagnosis of probable LM and suggested cell-cycle bypass activation as a potential mechanism associated with osimertinib resistance. After intrathecal methotrexate plus continued oral osimertinib, her neurological symptoms improved markedly, and intracranial pressure returned to normal. The first seizure occurred on March 19, 2026, and MRI on April 8, 2026 confirmed new brain parenchymal metastases. Whole-brain radiotherapy with a local boost to the metastases, antiepileptic treatment, and continued osimertinib led to obvious shrinkage of the intracranial lesions. Grade 3 thrombocytopenia and severe malnutrition occurred during multimodal therapy and improved with supportive care. At the last follow-up, the patient was clinically stable with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1.ConclusionsCSF NGS can overcome the diagnostic bottleneck of cytology-negative LM. It can also identify potential resistance alterations and actionable targets (such as CDK4/6 inhibitors) at the same time, providing direction for subsequent targeted strategies. As part of multimodal therapy, intrathecal chemotherapy combined with an EGFR tyrosine kinase inhibitor (TKI) can contribute to disease control in the CSF compartment, whereas parenchymal progression still requires salvage radiotherapy. Cumulative hematological and nutritional toxicity should be monitored during sequential multimodal therapy.
Related
- Efficacy and safety of intrathecal chemotherapy in leptomeningeal disease: a global retrospective multicenter analysis and review of the literature
- Clinical outcomes and prognostic factors of Ommaya reservoir-based intrathecal chemotherapy in lung cancer leptomeningeal metastasis: a retrospective cohort study
- Ommaya Reservoir-Based Cerebrospinal Fluid Chemotherapy for Leptomeningeal Metastasis in the Era of Targeted Therapy: Safety, Survival, and Exploratory Prognostic Factors from a Single-Center Cohort
- DRESS during chemotherapy with carboplatin, pemetrexed, and osimertinib for lung adenocarcinoma: A case report
- Development and Temporal Validation of a Three-Metabolite Cerebrospinal Fluid Model for the Diagnosis of Leptomeningeal Metastasis from Solid Tumors
BibTeX
@article{gan2026egfrmutant,
title = {{EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report}},
author = {Xinli Gan and Xin Jin and Mingmei Pan and Yan Guo and Chunjiao Yang},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1983545},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1983545},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - EGFR-mutant lung adenocarcinoma with leptomeningeal metastasis after osimertinib treatment: intrathecal chemotherapy combined with targeted therapy supported by cerebrospinal fluid next generation sequencing — a case report
AU - Xinli Gan
AU - Xin Jin
AU - Mingmei Pan
AU - Yan Guo
AU - Chunjiao Yang
PY - 2026
DA - 2026/11/04
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1983545
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1983545
AB - BackgroundLeptomeningeal metastasis (LM) is a severe complication of advanced non-small cell lung cancer (NSCLC). Conventional cerebrospinal fluid (CSF) cytology has limited sensitivity and often delays diagnosis. We report a case of LM molecularly supported by CSF next-generation sequencing (NGS) after three negative cytological examinations. NGS also revealed a potential bypass resistance alteration that informed subsequent treatment considerations.CaseA 57-year-old female never-smoker had EGFR exon 21 p.L858R-mutant lung adenocarcinoma. After 18 months of first-line osimertinib (80 mg once daily), she developed progressive nausea, vomiting, and dizziness. Contrast-enhanced cranial magnetic resonance imaging (MRI) showed linear leptomeningeal enhancement. Lumbar puncture showed markedly elevated intracranial pressure (>300 mmH2O) and increased CSF protein. However, three CSF cytological examinations (including cell block sections) found no malignant cells. CSF NGS detected the EGFR p.L858R mutation identical to the primary tumor, together with CDK4 amplification. Integrated with the clinical and MRI presentation, these findings supported a diagnosis of probable LM and suggested cell-cycle bypass activation as a potential mechanism associated with osimertinib resistance. After intrathecal methotrexate plus continued oral osimertinib, her neurological symptoms improved markedly, and intracranial pressure returned to normal. The first seizure occurred on March 19, 2026, and MRI on April 8, 2026 confirmed new brain parenchymal metastases. Whole-brain radiotherapy with a local boost to the metastases, antiepileptic treatment, and continued osimertinib led to obvious shrinkage of the intracranial lesions. Grade 3 thrombocytopenia and severe malnutrition occurred during multimodal therapy and improved with supportive care. At the last follow-up, the patient was clinically stable with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1.ConclusionsCSF NGS can overcome the diagnostic bottleneck of cytology-negative LM. It can also identify potential resistance alterations and actionable targets (such as CDK4/6 inhibitors) at the same time, providing direction for subsequent targeted strategies. As part of multimodal therapy, intrathecal chemotherapy combined with an EGFR tyrosine kinase inhibitor (TKI) can contribute to disease control in the CSF compartment, whereas parenchymal progression still requires salvage radiotherapy. Cumulative hematological and nutritional toxicity should be monitored during sequential multimodal therapy.
SN - 2234-943X
ER -